Evaluation of CPV-104 Pharmacokinetics, Safety, and Tolerability in Healthy Subjects and Patients with C3 Glomerulopathy

The primary objective of this clinical trial is to evaluate the **safety** and **tolerability** of CPV-104 in both healthy individuals and patients diagnosed with **C3 glomerulopathy (C3G)**. This is clinically relevant as C3G is a rare kidney disorder characterized by the deposition of complement component 3 in the glomeruli, leading to kidney damage. Understanding the safety profile of CPV-104 is crucial for determining its potential as a therapeutic option for this condition.

The clinical trial involves participants diagnosed with **C3 glomerulopathy (C3G)**. The study population includes both male and female subjects, with an age range spanning from children to adults. The trial does not focus on a vulnerable population. The sponsor has not provided information regarding the total number of participants. Selection criteria for the trial population, as well as specific lifestyle considerations such as diet, physical activity, or habits, have not been disclosed. Key inclusion or exclusion criteria are not specified in the available data.

The clinical trial is designed to evaluate the **safety** and tolerability of CPV-104 in both healthy individuals and patients diagnosed with **C3 glomerulopathy (C3G)**. This study is structured as a Phase 1 trial, which is typically the initial phase in clinical research focusing on assessing the safety profile of a new investigational drug. The trial is expected to commence recruitment on April 29, 2025, and is projected to conclude by May 31, 2026. The trial employs a randomized, double-blind, controlled design to ensure unbiased results and to maintain the integrity of the data collected.

Participants will undergo a series of study visits, beginning with an inclusion visit, also known as the screening visit. During this visit, eligibility criteria will be assessed to determine the suitability of participants for the trial. Following successful screening, participants will be enrolled and randomized into the study. Throughout the trial, there will be scheduled follow-up visits to monitor the participants' health, assess the drug's effects, and collect necessary data. These visits are crucial for evaluating the primary and secondary endpoints of the study. The trial will culminate in an end-of-study visit, where final assessments will be conducted, and participants will be debriefed on their involvement in the study.

The expected duration of participant involvement will vary depending on individual response and adherence to the study protocol. However, participants are generally expected to remain in the study until its conclusion unless specific conditions necessitate early termination. Such conditions may include adverse reactions to the investigational drug, non-compliance with study procedures, or withdrawal of consent by the participant. The trial is conducted under strict ethical guidelines, ensuring the safety and well-being of all participants throughout the study duration.

No specific information regarding the experimental medication, including its name, pharmaceutical form, dosage, route, and frequency of administration, is provided in the available data. Consequently, a detailed description of the experimental treatment cannot be formulated based on the current dataset.

Similarly, there is no information available about any non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatment, used in the study. Therefore, a description of these elements cannot be provided.

Additional relevant information about drug administration, dosing schedules, and participant compliance monitoring is also not included in the data. As such, these aspects cannot be detailed in the context of this clinical trial.

The clinical trial is designed to assess the efficacy of an investigational product. The trial is categorized as a Phase 1 study, which typically focuses on evaluating the safety, tolerability, and pharmacokinetics of the product in a small group of participants. The estimated recruitment start date is April 29, 2025, with an anticipated end date of May 31, 2026. Although specific efficacy endpoints are not detailed, Phase 1 trials often involve the collection of preliminary data on efficacy, which may include measurements such as **biomarker** levels or initial symptom improvement. The methods and schedule for measuring these parameters are not specified, but they generally involve validated scales, laboratory tests, or patient-reported outcomes. The trial will adhere to rigorous protocols to ensure the accurate collection and analysis of efficacy data, contributing to the overall assessment of the investigational product's potential therapeutic benefits.